Last reviewed · How we verify
Ofloxacin 400mg
Ofloxacin 400mg is a Small molecule drug developed by Indiana University School of Medicine. It is currently FDA-approved.
Ofloxacin 400mg, developed by the Indiana University School of Medicine, is a marketed antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ofloxacin 400mg |
|---|---|
| Sponsor | Indiana University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis (PHASE1, PHASE2)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort (PHASE3)
- Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ofloxacin 400mg CI brief — competitive landscape report
- Ofloxacin 400mg updates RSS · CI watch RSS
- Indiana University School of Medicine portfolio CI
Frequently asked questions about Ofloxacin 400mg
What is Ofloxacin 400mg?
Who makes Ofloxacin 400mg?
What development phase is Ofloxacin 400mg in?
Related
- Manufacturer: Indiana University School of Medicine — full pipeline
- Compare: Ofloxacin 400mg vs similar drugs
- Pricing: Ofloxacin 400mg cost, discount & access